In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Cyclacel in-licenses novel anticancer drug from Lorus Therapeutics
Sankyo and Fujisawa Agree to Discontinue Business Arrangements on Sankyo's Antifungal CS-758
Lorus and Cyclacel Limited enter into licensing agreement
Biota secures global influenza partnership with Sankyo
CYCLACEL ANNOUNCES COLLABORATION ON NEPHROLOGY APPLICATIONS OF CDK INHIBITORS
Sankyo gains rights to cholesterol lowering agent
Cyclacel and Xcyte Therapies combine to form international biopharmaceutical company
CYCLACEL AND ALTANA PHARMA ANNOUNCE COLLABORATION ON MITOTIC TARGET IDENTIFICATION